Table 4.
Summary of clinical and molecular characteristics of patients with complete or partial loss of nuclear ATRX protein
| Patient No. | Age (yr) | INSS stage | MYCN amplification | ALK IHC | ATRX IHC | TERT IHC | Outcome |
|---|---|---|---|---|---|---|---|
| 13 | 1.3 | I | – | – | Loss | + | NED |
| 17 | 1.9 | I | – | – | Loss | + | NED |
| 86 | 12.9 | I | – | + | Loss | – | NED |
| 21 | 0.2 | II | – | – | Loss | + | NED |
| 26 | 2.2 | III | – | – | Loss | + | NED |
| 23 | 12.2 | IV | – | + | Loss | + | DOD |
| 38 | 3.6 | IV | – | + | Loss | – | DOD |
| 39 | 10.8 | IV | – | + | Loss | – | NED |
| 47 | 4.6 | IV | – | + | Loss | + | DOD |
ATRX, alpha thalassemia/mental retardation syndrome X-linked; INSS, International Neuroblastoma Staging System; ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry; TERT, telomerase reverse transcriptase; NED, no evidence of disease.